Serrapeptase
Contains 40,000 IU Per Serving!
Serrapeptase has been referred to as the miracle enzyme, possibly benefiting people with arthritis, osteoarthritis, rheumatoid arthritis, and sinusitis. Also showing anti-inflammatory properties, Serrapeptase may prove to be an effective pain reliever and help to relieve the suffering of those with sinusitis. Produced in the intestines of silk worms, this enzymes helps the matured worm break free from its' hard cocoon walls.
Recent studies suggest that these enzymes may significantly reduce the amount of arterial plaque (unwanted fatty deposits in the arteries), in addition to greatly reducing the chance of developing blood clots which can cause heart attack and stroke.
The most astounding results in testing were those that focused on inflammation. In other words, not only have clinical studies shown that serrapeptase is fibrinolytic (dissolved fibrin and small blood clots), anti-edemic (prevents and cuts down swelling and fluid retention), they’ve shown it to have powerful anti-inflammatory properties with the most profound benefit of blocking the release of pain-inducing amines from inflamed tissues.**
|
Supplement Facts
Serving Size 2 Capsules
|
|
Amount Per Serving
|
|
|
Amount
|
% Daily Value
|
|
Serrapeptase
(Providing a minimum of 20,000 IU per capsule)
|
900 mg
|
*
|
|
|
*%Daily Value not established.
|
|
Other Ingredients: Vegetable cellulose, Magnesium Stearate, Stearic Acid, and Microcrystalline Cellulose
|
|
SUGGESTED USE: As a dietary supplement, take up to 2 capsules at bedtime with water.
|
|
|
|
CAUTION: Do not exceed recommended dose. Do not use this product if you are taking blood platelet inhibitors such as Ticlid, Palvix or Coumadin. Pregnant or nursing mothers, children under 18, and individuals with a known medical condition should consult a physician before using this or any dietary supplement.
|
**[Mazzone A, Catalani M, Costanzo M, Drusian A, Mandoli A, Russo S, Guarini E, Vesperini G. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. 1990] [Mazzone A, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. 1990]